Abstract
Conventional antipsychotic drugs, which have been used for a half century to treat a range of major psychiatric disorders like schizophrenia, are being replaced by modern “atypical antipsychotics”. Although the term “atypical” has been applied broadly to antipsychotic drugs marketed in the past decade, these newer drugs are strikingly heterogeneous in chemical, pharmacological, and clinical points of view. Recently, much attention has been directed to partial dopamine receptor agonists as promising atypical antipsychotics with properties of “dopamine system stabilizers”, which behave either as agonists or antagonists depending on the functional state of the dopamine receptors. Aripiprazole (OPC-14597) is the first and unique antipsychotic drug with such pharmacological properties commercially available in US, Europe, and most recently in Japan. In the present article, the term “atypicality” is critically revisited, and the place of partial dopamine receptor agonists in atypical antipsychotics is overviewed with special reference to the intrinsic activities appropriate for treating the schizophrenic patients with greatest efficacy and least liability of adverse effects such as extrapyramidal symptoms.
Keywords: Atypical antipsychotics, aripiprazole, dopamine receptor, partial agonist, intrinsic activity, presynaptic autoreceptor, schizophrenia, dopamine system stabilizer
Central Nervous System Agents in Medicinal Chemistry
Title: Partial Dopamine Receptor Agonists as Newer Atypical Antipsychotics:Intrinsic Activity Appropriate for Treatment of Schizophrenic Patients
Volume: 7 Issue: 3
Author(s): Yuji Odagaki
Affiliation:
Keywords: Atypical antipsychotics, aripiprazole, dopamine receptor, partial agonist, intrinsic activity, presynaptic autoreceptor, schizophrenia, dopamine system stabilizer
Abstract: Conventional antipsychotic drugs, which have been used for a half century to treat a range of major psychiatric disorders like schizophrenia, are being replaced by modern “atypical antipsychotics”. Although the term “atypical” has been applied broadly to antipsychotic drugs marketed in the past decade, these newer drugs are strikingly heterogeneous in chemical, pharmacological, and clinical points of view. Recently, much attention has been directed to partial dopamine receptor agonists as promising atypical antipsychotics with properties of “dopamine system stabilizers”, which behave either as agonists or antagonists depending on the functional state of the dopamine receptors. Aripiprazole (OPC-14597) is the first and unique antipsychotic drug with such pharmacological properties commercially available in US, Europe, and most recently in Japan. In the present article, the term “atypicality” is critically revisited, and the place of partial dopamine receptor agonists in atypical antipsychotics is overviewed with special reference to the intrinsic activities appropriate for treating the schizophrenic patients with greatest efficacy and least liability of adverse effects such as extrapyramidal symptoms.
Export Options
About this article
Cite this article as:
Odagaki Yuji, Partial Dopamine Receptor Agonists as Newer Atypical Antipsychotics:Intrinsic Activity Appropriate for Treatment of Schizophrenic Patients, Central Nervous System Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152407781669125
DOI https://dx.doi.org/10.2174/187152407781669125 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Defence Mechanisms
Current Respiratory Medicine Reviews Omega-3 Fatty Acids: Role in the Prevention and Treatment of Psychiatric Disorders
Current Psychiatry Reviews Gene Therapy for Parkinsons Disease: Progress and Challenges
Current Gene Therapy Editorial (Thematic Issue: Novel Perspectives for Parkinson’s Disease Therapy: Insights from the Latest Advances in Disease Pathophysiology, Diagnostic and Experimental Tools and Molecular Targets)
CNS & Neurological Disorders - Drug Targets Natural Products Combating Neurodegeneration: Parkinson’s Disease
Current Drug Metabolism Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease
Current Alzheimer Research Disorders of Consciousness and Electrophysiological Treatment Strategies: A Review of the Literature and New Perspectives
Current Pharmaceutical Design The Role of Flow-Independent Exhaled Nitric Oxide Parameters in the Assessment of Airway Diseases
Current Topics in Medicinal Chemistry Protein Interaction Studies for Understanding the Tremor Pathway in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Surgical Ventricular Restoration: An Operation To Reverse Remodeling - The Basic Science (Part I)
Current Cardiology Reviews Safety Profile of the Use of Second Generation Antipsychotics in the Child and Adolescent Population
Current Psychopharmacology Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry Homocysteine Level and Mechanisms of Injury in Parkinson's Disease as Related to MTHFR, MTR, and MTHFD1 Genes Polymorphisms and LDopa Treatment
Current Genomics Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness
Current Pharmaceutical Design Melatonin Receptor Agonists: SAR and Applications to the Treatment of Sleep-Wake Disorders
Current Topics in Medicinal Chemistry 5-HT<sub>6</sub> Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia
Current Pharmaceutical Design Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Alpha7 Neuronal Nicotinic Receptors as Targets for Novel Therapies to Treat Multiple Domains of Schizophrenia
Current Pharmaceutical Biotechnology